Clinical trials recruiting in Kaunas, Lithuania

Phase breakdown

Conditions recruiting in Kaunas, Lithuania

Recruiting trials in Kaunas, Lithuania

• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
  NCT07299019 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female)
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female)
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
  NCT04779320 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
  NCT06008197 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
  NCT03619850 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  NCT05457283 · Phase: Phase 3 · Ages: 1 Year to 18 Years · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07184996 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• Co-creating School Community Intervention Program on Physical Activity to Increase Health Equity in Children and Adolescents
  NCT07120516 · Phase: Not specified · Ages: 12 Years to 16 Years · Sex: All (male and female)
• Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients
  NCT07284446 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
  NCT07415044 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• MELIORA Data Collection Campaigns
  NCT07190066 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• MELIORA Virtual Coach Intervention for Breast Cancer Prevention
  NCT07200427 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
  NCT06515821 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06911112 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer
  NCT05378919 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
  NCT06274801 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
  NCT07516886 · Phase: Not specified · Ages: 18 Years and older · Sex: Male
• Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease
  NCT06072690 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female)
• Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®
  NCT05114850 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
  NCT06850727 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
  NCT06548542 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
  NCT06278532 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Kaunas, Lithuania?

32 recruiting trials have at least one study site in Kaunas, Lithuania.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.